Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Intrapleural Bevacizumab and Camrelizumab for Malignant Pleural Effusion
NCT05330065Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Aug 2022
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors
01
Overview
A Phase 2 trial of camrelizumab in malignant pleural effusion (MPE), sponsored by The First Affiliated Hospital of Zhengzhou University. Status: unknown.
02
Drugs
camrelizumab
03
Conditions
malignant pleural effusion (MPE)
Beyond the preview
Go deeper on NCT05330065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05330065.